BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19521766)

  • 21. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
    Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
    Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
    King AE; Umland EM
    Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer.
    Van Poznak C
    Cancer Invest; 2006 Feb; 24(1):110-2. PubMed ID: 16467002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ): A concise update.
    Bagan J; Scully C; Sabater V; Jimenez Y
    Oral Oncol; 2009 Jul; 45(7):551-4. PubMed ID: 19251474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Jaw osteonecrosis in patients treated with bisphosphonates: an ultrastructural study.
    Perrotta I; Cristofaro MG; Amantea M; Russo E; De Fazio S; Zuccalà V; Conforti F; Amorosi A; Donato G; Tripepi S; Giudice M
    Ultrastruct Pathol; 2010 Aug; 34(4):207-13. PubMed ID: 20594040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients.
    Wutzl A; Eisenmenger G; Hoffmann M; Czerny C; Moser D; Pietschmann P; Ewers R; Baumann A
    Wien Klin Wochenschr; 2006 Aug; 118(15-16):473-8. PubMed ID: 16957978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral bisphosphonates and osteonecrosis of the jaw: are the MHRA recommendations appropriate?
    Compston J
    Menopause Int; 2007 Jun; 13(2):54-5. PubMed ID: 17540133
    [No Abstract]   [Full Text] [Related]  

  • 28. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.
    Coleman R; Woodward E; Brown J; Cameron D; Bell R; Dodwell D; Keane M; Gil M; Davies C; Burkinshaw R; Houston SJ; Grieve RJ; Barrett-Lee PJ; Thorpe H
    Breast Cancer Res Treat; 2011 Jun; 127(2):429-38. PubMed ID: 21394500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Bisphosphonates and osteonecrosis of the jaws in patients with myelomatosis].
    Neumann B; Gregersen H
    Ugeskr Laeger; 2006 May; 168(21):2078-9. PubMed ID: 16768928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
    Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
    Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonate (zoledronic acid)-induced osteonecrosis of the jaw.
    Haidar A; Jønler M; Folkmar TB; Lund L
    Scand J Urol Nephrol; 2009; 43(6):442-4. PubMed ID: 19903091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonate-induced osteonecrosis of the jaw.
    Krueger CD; West PM; Sargent M; Lodolce AE; Pickard AS
    Ann Pharmacother; 2007 Feb; 41(2):276-84. PubMed ID: 17299010
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bisphosphonates and osteonecrosis of the jaw--current thoughts.
    Arrain Y; Masud T
    Dent Update; 2009 Sep; 36(7):415-9. PubMed ID: 19810397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer.
    Sanna G; Preda L; Bruschini R; Cossu Rocca M; Ferretti S; Adamoli L; Verri E; Franceschelli L; Goldhirsch A; Nolè F
    Ann Oncol; 2006 Oct; 17(10):1512-6. PubMed ID: 16936182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
    Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
    J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker.
    Pazianas M; Blumentals WA; Miller PD
    Osteoporos Int; 2008 Jun; 19(6):773-9. PubMed ID: 17999023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bisphosphonates and osteonecrosis of the jaws: science and rationale.
    Gutta R; Louis PJ
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Aug; 104(2):186-93. PubMed ID: 17448709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tooth extraction: Is it inciting event or sequela of osteonecrosis of the jaws associated with intravenous bisphosphonates?
    Altundag K; Bulut N; Tezcan E; Ozen M; Purnak T
    J Oral Maxillofac Surg; 2007 Jan; 65(1):154. PubMed ID: 17174785
    [No Abstract]   [Full Text] [Related]  

  • 39. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
    Brown JJ; Ramalingam L; Zacharin MR
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bisphosphonate-induced osteonecrosis of the jaw: a medical enigma?
    Siddiqi A; Payne AG; Zafar S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):e1-8. PubMed ID: 19570696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.